CDKN2A and dysplasia: Genomic loss, chromosomal gains and amplifications, mutations, and aneuploidy are observed in BE [22,23], and loss of heterozygosity of CDKN2A is reported in 47 – 75% of patients with BE, in the absence of dysplasia or EAC [24-26].